Correspondence

Are we missing opportunities to prevent cervical cancer in HIV-infected women in India?

Sir,

Primary and secondary prevention of cervical cancer became a reality within 40 years of the initial discovery of the link between human papillomaviruses (HPVs) and cervical cancer\(^1\). However, it still remains the fourth most common cancer among women with an estimated 528,000 cases globally, of which 85 per cent occur in developing countries\(^2\). It is the second most common cancer among women in India with 123,000 new cases and 67,000 deaths reported in 2012\(^2\). Cervical cancer incidence in India is 1.6 times more than what was seen in England about 40 years ago\(^3\).

Screening for cervical cancer using visual inspection of the cervix with 3-5 per cent acetic acid (VIA), and treatment using cryotherapy or loop electrosurgical excision procedure (LEEP), in a single or two-visit approach have been shown to be effective in reducing cervical cancer incidence and mortality in two large randomized controlled trials in Dindigul district\(^4\) and in Mumbai\(^5\). The World Health Organization (WHO) has published comprehensive guidelines for cervical cancer prevention and control for low- and middle-income countries and has recommended ‘screen and treat’ strategy in a single visit approach using VIA and treatment using cryotherapy\(^6\).

A majority of the health care providers in public settings continue to use cytology screening in spite of the evidence generated from large studies conducted in India and elsewhere about its limitations in resource-limited setting. It is disturbing that this strategy remains unknown to the majority of the health care providers even in the public sector in India or those who have heard of it show little confidence over its utility.

Considering the burden of cervical cancer, the translation of research findings into programmes should have been a national priority. The screening coverage is as low as 4 to 6 per cent in India\(^15\). Of the 28 States and seven Union Territories, only two States, namely, Tamil Nadu and Sikkim, have included cervical cancer screening in their public health programmes\(^16,17\).

There is a close interplay between HPV and human immunodeficiency virus (HIV) infection due to several overlapping biological and socio-economic factors. The regions in the world that have a high burden of HIV infection are also the regions with a high burden of cervical cancer and India is no exception. Although HPV infection remains transient in the majority of the immune-competent individuals and cervical cancer is a
rare outcome of the long-term HPV infection, the disease is more common and more severe in HIV-infected individuals. Progressive loss of CD4+ T cells in HIV-infected individuals results in increased prevalence of HPV infection and HPV-associated malignancies. The overall HPV prevalence among HIV-infected women across different regions in the world was 36 per cent in contrast with 12 per cent among women in the general population. HIV-infected women are at 2- to 22-fold increased risk of developing cervical cancer as compared to HIV-uninfected women. Therefore, the HIV-infected women are the group that needs cervical cancer screening and treatment of cervical intra-epithelial neoplasia (CIN) the most.

India accounts for the third largest burden of HIV-infected individuals worldwide. At the end of December 2012, 1.74 million people were ever registered at 380 anti-retroviral treatment (ART) centres of National AIDS Control Organization (NACO) throughout the country. Of these 1.74 million people, 604,987 were clinically eligible patients (including 34,367 children) who were receiving free ART in government health facilities. The National AIDS Control Programme, Phase IV (NACP-IV) aims to strengthen the response to this epidemic in India through a well-defined integration process over the five years period (2012-2017). The main objectives are to reduce new infections and provide comprehensive care and support to all people living with HIV (PLHIV) and treatment facilities for all those who require it. Though ART has been effective in improving survival, preventing certain opportunistic infections and quality of life of HIV-infected individuals, tangible benefits have not been seen in reducing HPV-related diseases.

Prevalence of high-risk HPV infection in HIV-infected women in India varies from 30 to 40 per cent. High rates of CIN 2+ lesions, considered as precursors of cervical cancer, have already been reported from Indian studies among HIV-infected women and these vary from 5 to 16 per cent. Of the 1.74 million HIV-infected individuals registered at NACO ART centres, about 0.816 million are women and considering the CIN detection rates, currently at the least 40,800 women are likely to have CIN 2/3 lesions. Cervical cancer may be prevented among a substantial number of these women if detected and treated early. Integration of cervical cancer screening programme at NACO ART centres will strengthen comprehensive care and treatment programme for HIV-infected women. ‘Screen and treat’ strategy offers an opportunity to provide immediate treatment for screen-positive women. Though it has an element of overtreatment, this overtreatment is likely to be more beneficial in HIV-infected women than women in the general population. This is particularly important if we consider six per cent cumulative loss to follow-up of registered cases as per NACO’s estimation.

At least 25 countries from South America, Africa and Asia have included VIA screening in their national programmes, of which eight countries are from African region. In addition, pilot programmes using VIA screening are ongoing in 22 African countries and these regions are also are affected by the HIV epidemic. The cervical cancer prevention programme in Zambia is integrated with the HIV/AIDS care and treatment programme and has provided screening services to over 58,000 women in five years. Botswana has also implemented nationwide VIA screening through the HIV care clinics. Some countries in Africa have initiated an innovative public-private partnership programme to combat cancers among women in Africa.

An opportunity of cervical cancer prevention in HIV-infected women in India should not be missed. Inclusion and implementation of cervical cancer prevention programme using single-visit ‘screen and treat’ strategy at NACO ART centres is possible considering NACO’s experience of scaling up ART as well as prevention of mother-to-child transmission (PMTCT) programme for HIV-infected women. This will provide an opportunity of integration of this cervical cancer prevention programme with National Health Mission and National Cancer Control Programme. Investment at this stage for cervical cancer screening and treatment can be further utilized for preventing cervical cancer among women in the general population in India through a comprehensive cervical cancer control programme.

Smita Joshi, Vinay Kulkarni, Raman Gangakhedkar & Rengaswamy Sankaranarayanan
1Hirabai Cowasji Jehangir Medical Research Institute, Pune, Prayas, Pune, 3National AIDS Research Institute (ICMR), Pune, India & 4International Agency for Research on Cancer, Lyon, France
*For correspondence: smitanjoshi@gmail.com
References

1. zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res 1976; 36: 794.

2. Cancer Fact Sheets. Globocan 2012 (IARC). Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx? cancer= cervix, accessed on March 26, 2014.

3. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer in cervix in England: evaluation based on routinely collected statistics. BMJ 1999; 318: 904-8.

4. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, SanthaKumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370: 398-406.

5. Shastry SS, Mittra I, Mishra GA, Gupta S, Dikshit R, Singh S, et al. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst 2014; 106: dju009.

6. World Health Organization (WHO). WHO guidance note: Comprehensive cervical cancer prevention and control - a healthier future for girls and women. Available from: http://www.who.int/reproductivehealth/publications/cancers/9789241505147/en/, accessed on March 27, 2014.

7. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, vol. VIII. IARC Scientific Publications No. 155. Lyon: IARC Press; 2002.

8. IARC Handbooks of cancer prevention. Volume 10. Cervix cancer screening. Lyon: IARC Press; 2005. Available from: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=76&codech=18, accessed on August 22, 2013.

9. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 2001; 79: 954-62.

10. Robles SC, White F, Peruga A. Trends in cervical cancer mortality in the Americas. Bull Pan Am Health Organ 1996; 30: 290-301.

11. Gage JC, Ferreccio C, Gonzales M, Arroyo R, Huivin M, Robles SC. Follow-up care of women with an abnormal cytology in a low-resource setting. Cancer Detect Prev 2003; 27: 466-71.

12. Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbala CG, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008; 123: 153-60.

13. Joshi S, Sankaranarayanan R, Muwonge R, Kulkarni V, Somnathan T, Divate U. Screening of cervical neoplasia in HIV-infected women in India. AIDS 2013; 27: 607-15.

14. Sahasrabuddhe VV, Bhosale RA, Kavatkar AN, Nagwanshi CA, Joshi SN, Jenkins CA, et al. Comparison of visual inspection with acetic acid and cervical cytology to detect high-grade cervical neoplasia among HIV-infected women in India. Int J Cancer 2012; 130: 234-40.

15. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 2008; 5: e132.

16. Cervical Cancer Screening Pilot Program, TNHSP. Available from: http://www.tnhsp.org/files/Cervical%20Cancer.pdf; http://www.tnhsp.org/files/Cervical Cancer.pdf; accessed on October 22, 2015.

17. Health Care, Human Services and Family Welfare Department, Govt of Sikkim. Available from: http://sikkimhealth.gov.in/, accessed on October 23, 2015.

18. De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 2008; 17: 545-54.

19. van der Burg SH, Palefsky JM. Human immunodeficiency virus and human papilloma virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful. Transl Med 2009; 7: 108.

20. Clifford GM, Goncalves MA, Franceschi S; HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006; 20: 2337-44.

21. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99.

22. Denny LA, Franceschi S, de Sanjose S, Heard I, Moscicki AB, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 2012; 30 (Suppl 5): F168-F74.

23. National AIDS Control Organization (NACO). Annual Report 2012-13. Department of AIDS Control, Ministry of Health & Family Welfare. Available from: http://www.naco.gov.in/upload/Publication/Annual%20Report/Annual%20Report%202012-13_English.pdf, accessed on March 26, 2014.

24. Peedicyaill A, Thiyagarajan K, Gnanamony M, Pulimood SA, Jayaseelan V, Kannangai R, et al. Prevalence and risk factors for human papillomavirus and cervical intraepithelial neoplasia among HIV-positive women at a tertiary level hospital in India. J Low Genit Tract Dis 2009; 13: 159-64.

25. Sarkar K, Pal R, Bal B, Saha B, Bhattacharya S, Sengupta S, et al. Oncogenic HPV among HIV infected female population in West Bengal, India. BMC Infect Dis 2011; 11: 72.

26. Joshi SN, Gopalkrishna V, Kumar BK, Dutta S, Nyaynirgune P, Thakar M, et al. Cervical squamous intra-epithelial changes and human papillomavirus infection in women infected with human immunodeficiency virus in Pune, India. J Med Virol 2005; 76: 470-5.

27. Sahasrabuddhe VV, Bhosale RA, Joshi SN, Kavatkar AN, Nagwanshi CA, Kelkar RS, et al. Prevalence and predictors of colposcopic-histopathologically confirmed cervical intraepithelial neoplasia in HIV-infected women in India. PLoS One 2010; 5: e8634.

28. Isakidis P, Pimple S, Varghese B, Khan S, Mansoor H, Ladomirksa J, et al. HPV infection, cervical abnormalities, and cancer in HIV-infected women in Mumbai, India: 12-month follow-up. Int J Womens Health 2013; 5: 487-94.
29. Progress in cervical cancer prevention: The CCA report card. December 2012. Available from: http://www.cervicalcanceraction.org/pubs/CCA_reportcard_low-res.pdf, accessed on March 27, 2014.

30. Mwanahamuntu MH, Sahasrabuddhe VV, Kapambwe S, Pfaendler KS, Chibwesha C, Mkumba G, et al. Advancing cervical cancer prevention initiatives in resource-constrained settings: insights from the Cervical Cancer Prevention Program in Zambia. PLoS Med 2011; 8: e1001032.

31. Ramogola-Masire D, de Klerk R, Monare B, Ratsha B, Friedman HM, Zetola NM. Cervical cancer prevention in HIV-infected women using the “see and treat” approach in Botswana. J Acquir Immune Defic Syndr 2012; 59: 308-13.

32. Oluwole D, Kraemer J; Pink Ribbon Red Ribbon. Innovative public-private partnership: a diagonal approach to combating women’s cancers in Africa. Bull World Health Organ 2013; 91: 691-6.